Morgan, CJA, Schafer, G, Freeman, TP, Curran, HV. Impact of cannabidiol on the acute and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry
2010; 197: 285–90.
Potter, DJ, Clark, P, Brown, MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci
2008; 53: 90–4.
Di Forti, M, Morgan, C, Dazzan, P, Pariante, C, Mondelli, V, Marques, TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry
2009; 195: 488–91.
Morgan, CJA, Curran, HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry
2008; 192: 306–7.
Bhattacharyya, S, Morrison, PD, Fusar-Poli, P, Martin-Santos, R, Borgwardt, S, Winton-Brown, T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology
2009; 35: 764–74.
Leweke, M, Schneider, U, Radwan, M, Schmidt, E, Emrich, HM. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav
2000; 66: 175–81.
Pertwee, RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol
2008; 153: 199–215.
Zuardi, AW, Crippa, JA, Hallak, JE, Moreira, FA, Guimaraes, FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res
2006; 39: 421–9.
Leweke, FM, Koethe, D, Pahlisch, F, Schreiber, D, Gerth, CW, Nolden, BM, et al. Antipsychotic effects of cannabidiol. European Psychiatry
2009; 24 (suppl 1): S207.
Henquet, C, van Os, J, Kuepper, R, Delespaul, P, Smits, M, á Campo, J, et al. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry
2010; 196: 447–53.